Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cumberland PharmaceuticalsCPIX -1.48%36 3-Year EBITDA Growth Rate is 105.60% as of Mar. 2026, which is 1409% above its 10-year median of 7.00. GuruFocus rates CPIX with a GF Score™ of 36/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 813 Drug Manufacturers companies, Cumberland Pharmaceuticals ranks better than 97.91% on this metric.
During the past 12 months, Cumberland Pharmaceuticals's average EBITDA Per Share Growth Rate was -138.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 105.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cumberland Pharmaceuticals was 109.00% per year. The lowest was -25.60% per year. And the median was 7.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cumberland Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
CPIX vs INCR, CTOR, TLPH: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 105.60% mean?
Cumberland Pharmaceuticals (CPIX) has a 3-Year EBITDA Growth Rate of 105.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cumberland Pharmaceuticals and its competitors. This is 1409% above median its historical median of 7.00. According to the industry distribution chart, Cumberland Pharmaceuticals ranks #17 out of 813 companies in the Drug Manufacturers industry, placing it in the top 2.1%.
Is Cumberland Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Cumberland Pharmaceuticals' current 3-Year EBITDA Growth Rate of 105.60% is 1409% above median its 10-year median of 7.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Cumberland Pharmaceuticals' value of 105.60% is 1100% above this industry median. Based on the distribution chart, Cumberland Pharmaceuticals ranks #17 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cumberland Pharmaceuticals has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' 3-Year EBITDA Growth Rate compare to INCR and CTOR?
According to the Drug Manufacturers industry distribution chart, Cumberland Pharmaceuticals ranks #17 out of 813 companies for 3-Year EBITDA Growth Rate. This places Cumberland Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. Cumberland Pharmaceuticals' value of 105.60% is 1100% above this benchmark. While the company's 10-year median is 7.00 vs. the industry median of 8.80, Cumberland Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cumberland Pharmaceuticals's current 3-Year EBITDA Growth Rate of 105.60% is 1100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cumberland Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cumberland Pharmaceuticals's current 3-Year EBITDA Growth Rate is 105.60%, which is 1409% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $7.02 — trading 225% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 105.60%, which is 1409% above median its 10-year median of 7.00 and 1100% above the Drug Manufacturers industry median of 8.80. Cumberland Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current 3-Year EBITDA Growth Rate is 105.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued.
The current stock price of $7.02 is trading 225% above its estimated GF Value™ of $2.16.
GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CPIX:
3-Year EBITDA Growth Rate: 105.60% (1409% above median its 10-year median of 7.00)
GF Value™: $2.16 vs. price of $7.02 (225% above fair value)
Industry Position: 1100% above the Drug Manufacturers median (#17 of 813)
No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
36GF Score
Get the complete analysis for CPIX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPIX has been successfully added to your 
